Literature DB >> 8595781

Long-term results of allograft replacement in the management of bone tumors.

H J Mankin1, M C Gebhardt, L C Jennings, D S Springfield, W W Tomford.   

Abstract

Over the past 24 years, the authors have implanted >870 massive frozen cadaveric allografts mostly for the treatment of defects created by the resection of a bone tumor. Most of the grafts were obtained from the authors' institutional bone bank. The results show that only stage and type of graft affected outcome predictably. Specifically, grafts for a Stage 2 or Stage 3 tumor had a poorer outcome than those for Stages 0 and 1. The results for allograft arthrodeses were considerably poorer than osteoarticular, intercalary, and allograft plus prosthesis. The other major factors in results were complications--recurrence, infection, fracture, and nonunion--with the former 2 having a profound negative effect on outcome. After the first year of susceptibility to infection (10%) and the third year of increased risk of fracture (19%), the grafts become stable, and approximately 75% are retained by patients and are considered to be successful for >20 years after implantation. Osteoarthritis becomes a problem at approximately 6 years for osteoarticular grafts, and so far, 16% of the patients with distal femoral, proximal tibial, or proximal femoral grafts have required total joint replacements. Although the current results are adequate, they are imperfect, and research should be directed at improving the results.

Entities:  

Mesh:

Year:  1996        PMID: 8595781     DOI: 10.1097/00003086-199603000-00011

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  126 in total

1.  Cortical allografts in spinal tuberculosis.

Authors:  S Govender; K P S Kumar
Journal:  Int Orthop       Date:  2003-04-25       Impact factor: 3.075

2.  Distal femoral osteoarticular allografts: long-term survival, but frequent complications.

Authors:  Patrick C Toy; Jeremy R White; Mark T Scarborough; William F Enneking; C Parker Gibbs
Journal:  Clin Orthop Relat Res       Date:  2010-11       Impact factor: 4.176

3.  Combined massive allograft and intramedullary vascularized fibula transfer: the capanna technique for lower-limb reconstruction.

Authors:  Karim Bakri; Anthony A Stans; Samir Mardini; Steven L Moran
Journal:  Semin Plast Surg       Date:  2008-08       Impact factor: 2.314

4.  Reconstruction of the knee extensor mechanism in patients with a malignant bone tumor of the proximal tibia.

Authors:  Yukihiro Yoshida; Shunzo Osaka; Junnosuke Ryu
Journal:  Surg Today       Date:  2010-06-26       Impact factor: 2.549

5.  Surgical revascularization induces angiogenesis in orthotopic bone allograft.

Authors:  Wouter F Willems; Thomas Kremer; Patricia Friedrich; Allen T Bishop
Journal:  Clin Orthop Relat Res       Date:  2012-09       Impact factor: 4.176

Review 6.  Management of infection following reconstruction in bone tumors.

Authors:  Sudhir K Kapoor; Rajesh Thiyam
Journal:  J Clin Orthop Trauma       Date:  2015-07-07

7.  Comparison of gait parameters in distal femoral replacement using a metallic endoprosthesis versus allograft reconstruction.

Authors:  Fahad AlGheshyan; Moataz Eltoukhy; Khaled Zakaria; Harry Thomas Temple; Shihab Asfour
Journal:  J Orthop       Date:  2015-02-23

Review 8.  Limb salvage in the skeletally immature patient.

Authors:  Valerae O Lewis
Journal:  Curr Oncol Rep       Date:  2005-07       Impact factor: 5.075

9.  Phenolization and coralline hydroxyapatite grafting following meticulous curettage for the treatment of enchondroma of the hand. A case series of 82 patients with 5-year follow-up.

Authors:  Dimitrios Georgiannos; Vasilios Lampridis; Ilias Bisbinas
Journal:  Hand (N Y)       Date:  2015-03

10.  Extended intralesional treatment versus resection of low-grade chondrosarcomas.

Authors:  Chad Aarons; Benjamin K Potter; Sheila C Adams; J David Pitcher; H Thomas Temple
Journal:  Clin Orthop Relat Res       Date:  2009-01-14       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.